Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2014

View Archived Issues

U.S. DTRA selects Bavarian Nordic's MVA-BN platform for biodefense vaccine development

Phase III study of volume-reduced subcutaneous C1-INH to prevent HAE attacks begins

Integrated chemical biology identifies a novel antimalarial drug target

CHDI Foundation and Genzyme to develop gene-silencing therapeutic for HD

PDA-001 treatment leads to significant improvements in functional outcome after stroke in rats

Bionor Pharma reports data from phase I trial of Vacc-C5

Australian Government funding to benefit Bionomics program

Novel multitarget agents for pain, inflammation and cancer claimed

FDA accepts Eylea supplemental BLA for review

Valneva begins fourth antibody discovery program for Sanofi Pasteur

Phenex Pharmaceuticals prepares new nuclear receptor ROR-gamma modulators

NeuraCeq obtains E.U. approval for PET imaging of beta-amyloid neuritic plaque density

Delayed administration of perlecan DV improves functional recovery in mice post-stroke

Sirenas Marine Discovery receives SBIR grant for its HIV small-molecule therapeutic

Fimasartan shows potential for treating stroke

Biogen Idec designs new autotaxin and/or S1P receptor modulators

Ardelyx licenses NaPi-2b phosphate inhibitor program to Sanofi

European Commission grants orphan drug designation to Soliris for prevention of DGF

Dual daclatasvir-based regimen granted FDA breakthrough therapy designation

Glenmark Pharmaceuticals discloses novel ITK inhibitors

FDA accepts Xiaflex supplemental BLA submission for review

Celladon enters into option agreement with Servier

Scientists at Roche and Genentech present novel ITK inhibitors for inflammatory disorders

Calithera Biosciences begins three phase I trials of CB-839

FDA awards orphan drug designation to Xoma's gevokizumab for pyoderma gangrenosum

Auris Medical enrolls first patient in European study of AM-101 in peripheral tinnitus

GenSpera studies G-202 in new phase II trial for recurrent or progressive glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...